BioHarvest Sciences (BHST) Stock Price, News & Analysis

Company Overview

BioHarvest Sciences Inc. is a biotechnology company that specializes in the development and commercialization of plant-based active ingredients through proprietary cell-culture technology. By growing undifferentiated plant cells in controlled bioreactor environments, the company aims to produce full-spectrum phytonutrients and botanical compounds that are difficult to obtain through traditional farming methods. This approach is designed to deliver consistent, high-purity extracts with reduced environmental impact and supply-chain variability.

The company’s product portfolio focuses on applications across the cosmeceutical, nutraceutical and health-and-wellness markets. Utilizing its “living plant cell” methodology, BioHarvest Sciences creates concentrates rich in natural antioxidants, peptides and other bioactive molecules. These ingredients are formulated for skin-care serums, dietary supplements and functional beverages, targeting consumers and manufacturers seeking clean-label and scientifically backed botanical solutions.

BioHarvest Sciences has pursued collaborative partnerships with research institutions and commercial enterprises to advance its cell-culture platform and expand market reach. While its technology development is headquartered in North America, the company’s ingredients have attracted interest from cosmetics and food firms in Europe and Asia. As it continues to scale production and refine its bioreactor processes, BioHarvest Sciences positions itself at the intersection of cellular agriculture and plant-derived therapeutics.

Key Stats

• Today's Range: $3.19 to $3.50
• 50-Day Range: $3.02 to $4.42
• 52-Week Range: $3.02 to $12.80
• Volume: 15,154 shs
• Average Volume: 24,041 shs
• Market Capitalization: $62.77 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10.00
• Consensus Rating: Hold

BioHarvest Sciences Stock Analysis - MarketRank™

BioHarvest Sciences scored higher than 63% of companies evaluated by MarketBeat, and ranked 355th out of 859 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

BioHarvest Sciences has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.

Upside Potential

BioHarvest Sciences has a consensus price target of $10.00, representing about 212.5% upside from its current price of $3.20.

Amount of Analyst Coverage

BioHarvest Sciences has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for BioHarvest Sciences are expected to grow in the coming year, from ($0.45) to ($0.13) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of BioHarvest Sciences is -5.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of BioHarvest Sciences is -5.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

BioHarvest Sciences has a P/B Ratio of 2.46. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.36% of the float of BioHarvest Sciences has been sold short.

Short Interest Ratio / Days to Cover

BioHarvest Sciences has a short interest ratio ("days to cover") of 3.15, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in BioHarvest Sciences has recently increased by 7.74%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

BioHarvest Sciences does not currently pay a dividend.

Dividend Growth

BioHarvest Sciences does not have a long track record of dividend growth.

News and Social Media

• Score: 3.7 / 5
• News Sentiment: N/A

News Sentiment

BioHarvest Sciences has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.86 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for BioHarvest Sciences this week, compared to 3 articles on an average week.

MarketBeat Follows

3 people have added BioHarvest Sciences to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: N/A
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, BioHarvest Sciences insiders have not sold or bought any company stock.

Percentage Held by Institutions

BioHarvest Sciences has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 5/14/2026
• Today: 6/15/2026
• Next Earnings (Estimated): 8/10/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:BHST
• Previous Symbol: NASDAQ:BHST
• CIK: 1723464
• Web: bioharvest.com
• Phone: 646-863-2177
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Price Target and Rating

• Average Price Target for BioHarvest Sciences: $10.00
• High Price Target: $10.00
• Low Price Target: $10.00
• Potential Upside/Downside: +212.5%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 2 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.59)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$11.14 million
• Net Margins: -32.54%
• Pretax Margin: -32.30%
• Return on Equity: -76.03%
• Return on Assets: -25.30%

Debt

• Debt-to-Equity Ratio: 0.03
• Current Ratio: 2.96
• Quick Ratio: 2.44

Sales & Book Value

• Annual Sales: $35.16 million
• Price / Sales: 1.79
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.30 per share
• Price / Book: 2.46

Miscellaneous

• Outstanding Shares: 19,616,000
• Free Float: N/A
• Market Cap: $62.77 million
• Optionable: N/A
• Beta: 0.70